Genentech
Get Quote: DNA
Price on 12/17/08: $79
Total return: 19%
Genentech was our only big winner. The biotech stock received one boost in February when the FDA approved cancer drug Avastin for breast cancer and another in July when majority-owner Roche made an unsolicited, $89-a-share bid for the shares it didn't already own.
In hindsight, it's too bad Genentech said no to Roche, but we're still enamored with Avastin's prospects.
Our advice: HOLD
NEXT: General Electric
Last updated December 22 2008: 10:11 AM ET
RSSNote: Starting date for all total return data is 12/3/07, except Genentech, which is 12/5/07.
